Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Tryptamine Therapeutics ( (AU:ENP) ).
Entropy Neurodynamics has notified the ASX that it will issue 50 million unquoted options exercisable at $0.05 and expiring on 19 December 2030 under an employee incentive scheme. The move increases the company’s pool of equity-based remuneration and may help align staff incentives with long-term shareholder value, while modestly diluting existing holders if the options are ultimately exercised.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited, listed on the ASX under the code ENP, operates in the broader biotechnology and neuroscience sector, though this filing focuses primarily on its capital structure rather than detailing its specific products or markets.
Average Trading Volume: 2,536,966
Technical Sentiment Signal: Sell
Current Market Cap: A$53.11M
For a thorough assessment of ENP stock, go to TipRanks’ Stock Analysis page.